43
Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

  • View
    222

  • Download
    4

Embed Size (px)

Citation preview

Page 1: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Salivary Gland Neoplasm

Dr. Saad Al-Muhayawi. M.D., FRCSC

Associate Professor & Consultant

ORL Head & Neck Surgery

Page 2: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 3: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 4: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 5: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 6: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 7: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 8: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 9: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery
Page 10: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Salivary gland neoplasm

1. Major salivary glanda. Parotid glandb. Submandibular glandc. Sublingual gland

2. Minor salivary gland600 – 1,000 minor salivary gland distributed throughout the mucosa of the upper aerodigestive tract (more common in the soft and hard palate).

Page 11: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

80% of salivary gland tumor occur in the parotid.

10 – 15% in the minor salivary gland.

5 – 10% in the submandibular gland.

80% of the parotid tumor are benign.

The most common is pleomorphic adenoma.

50% of the submandibular gland tumor are benign.

30% of the minor salivary gland are benign.

Page 12: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Malignant disease of the parotidPathogenesis:1. Reserve cell theory

(currently the favored theory) of salivary gland neoplasia states that salivary neoplasms arise from reserved (stem cells) of the salivary duct system e.g. adenonoid cystic carcinoma and acinic cell carcinoma arising from intercalated duct reserve cell. The mucoepidermoid carcinoma, squamous cell carcinoma, and salivary duct carcinoma arise from excretory reserve cell.

Salivary gland unit

Page 13: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

2. Multicellular theory of salivary gland neoplasia states that salivary neoplasm arise from already differentiated cells along the salivary gland unit. For example, squamous cell carcinoma arises from the excretory duct epithelium and acinic cell carcinoma arise from the acinar cells.

Salivary gland unit

Page 14: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

What are the most common benign tumor of the parotid?

1. Pleomorphic adenoma (benign mixed tumor).

2. Warthin’s tumor (papillary cyst adenoma lypmhomatosum).

3. Monomorphic adenoma

a. Basal cell adenoma

b. Canalicular adenomas

c. Oncocytoma

d. Myoepitheliomas

4. Granular cell tumor

5. Hemangioma

Page 15: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

What are the most common malignant neoplasm of the parotid gland?

1. Mucoepidermoid carcinoma – 40%It can high, intermediate, and low-grade base on the clinical behavior and the tumor differentiation which is related to the percentage of mucinous to epidermoid cell.

2. Adenoid cystic carcinoma – 10% Adenoid cystic carcinoma are unique among the salivary

gland tumors because of their indolent and protracted clinical course.

Characterized by preneural spread including skip lesions. The disease thus specific survival continuous to declined

for more than 20 years after initial treatment.

Page 16: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

3. Acinic cell carcinoma – 10 – 15 % of It is considered a low-grade tumor.

4. Malignant mixed tumor - 7% It is considered a high-grade malignancy.

5. Polymorphous low grade adenocarcinoma – 10% It is a low-grade variant of adenocarcinoma.

6. Adeno carcinoma – 10% It is a high-grade with poor prognosis.

7. Squamous cell carcinoma – 4% It is high-grade, more common in elderly patients, and

can confused with high-grade mucoepidermoid carcinoma.

Page 17: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

The malignant parotid tumor can be classified into:

1. High-grade: aggressive behavior, local invasion, and lymph node metastasis.

- high grade mucoepidermoid carcinoma- adenoid cystic carcinoma- carcinoma ex phelomorphic adenoma- adenocarcinoma- aquamous cell carcinoma- undifferentiated carcinoma

Page 18: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

2. Low-grade malignancy

- low grade mucoepidermoid carcinoma

- pholymorphous low grade adenocarcinoma

- acinic cell carcinoma

- low grade adenocarcinoma

- basal cell carcinoma

3. Intermediate grade

- intermediate grade mucoepidermoid carcinoma

- intermediate grade adenocarcinoma

- oncocytic carcinoma

Page 19: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Evaluation of patients with a parotid mass

1. History

Important points in the history:

- Parotid mass (duration, rate of the growth,

presence of pain)

- Facial paralysis

- Cervical lymphadenopathies

- Eyes and joints symptoms

- History of exposure to radiation

Page 20: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

2. Examination- Size of the mass- Skin fixation- Cervical adenopathies- Facial nerve functions

3. InvestigationC.T. and MRI are both effective modalities for imaging the size, the local, and the regional extension of the primary tumor and the neck metastasis.

C.T. saliography – it replaced now by high-resolution contrasted C.T. and MRI.

Page 21: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

4. FNAB- The accuracy is around 90% depend on the

techniques of aspirate and the cytopathologist.

5. Superficial parotidectomy is considered as a diagnostic and therapeutic for most benign tumors.

Page 22: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

The post-operative complications:

1. Skin flap necrosis

2. Hematoma

3. Salivary fistula and sialoseles – it presents as an opening in the suture line below the lobule of the ear.

4. Facial nerve paralysis – which could be:

a. Temporarily: 5 – 10% of the patients.

b. Permanent: less than 2% of the cases.

5. Numbness of the ear due to injury of great auricular nerve.

Page 23: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

6. Xerostomia not common in the superficial parotidectomy (30% of salivary producing tissue).

5. Frey’s syndrome (Gustatory sweating syndrome)

Incidence in 50% of the patients.

Etiology: post-operative growth of the interrupted preganglionic parasympathetic nerve branches to the parotid into the more superficial sweat glands. The diagnosis is usually made from the history but can be confirmed by the starch-iodine test.

Page 24: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

What is starch-iodine test?

Paint the affected skin with iodine, dust the skin with the starch, feed the patient. The appearance of bluish discoloration of the overlying skin due to reaction of starch and iodine in the presence of moisture (sweat.

Page 25: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

How do you treat Frey’s syndrome?

Although frey’s syndrome is usually a minor problem, it may require treatment which include:

1. Parasymphatholytic creams such as glycopyrrolate lotion may also be applied to the skin or scopolamine cream 3%.

2. Apply anti-perspirant to avoid sweating.

3. Jacobsen’s neurectomy via tympanotomy approach.

4. Elevating skin flap and placing tissue such as fascia, dermis, or creating SCM muscle flap and if there is a big defect you can use regional flap as a PMMF.

Page 26: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Facial nerve paralysis

In parotid malignancy

a. Patient with clinically pre-op facial nerve paralysis. What to do?

Intra-operative resection of the involved part of the facial nerve and primary grafting using greater auricular nerve or sural nerve.

Post-operative radiotherapy (high-grade)

Page 27: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

b. Patient with a normal facial function but intra-operative involvement of the facial nerve. What to do?

Careful dissection of the tumor of the facial nerve without sacrifying the facial nerve and followed-up with radiotherapy treatment.

Page 28: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

During an operation on the parotid, where do you find

the facial nerve?

Page 29: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

1. Tragal cartilage (pointer) – always point to the facial nerve.

The facial nerve is 1 cm. inferior and 1 cm. medial to the pointer.

Page 30: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

2. Tympanomastoid fissure – FN is 4 mm inferior to the tympano mastoid fissure as it exit from the stylo mastoid foramen.

Page 31: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

3. Posterior belly of digastric muscle. The facial nerve is superior to the upper border of the belly of the digastric muscle.

Page 32: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

4. Retrograde inferior approach to the facial nerve.

The lower branch of the facial nerve invariably can be found immediately external to the posterior facial vein as it exits the lower pole of the parotid gland.

Page 33: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

5. Retrograde anterior approach.

The parotid duct is constant imposition as it goes horizontally across the border of masseter muscle. It’s always accompanied by a branch of buccal or zygomatic branch within 1 cm. of the duct.

Angle of mandible

Parotid duct

Page 34: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Does the grading make difference in management of the parotid malignancy ?

Page 35: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Stage T N M

I T1 N0 M0

II T2 N0 M0

III T3 N0 M0

T1-3 N1 M0

IVA T1-3 N2 M0

T4a N0-2 M0

IVB T4b Any N M0

Any T N3 M0

IVC Any T Any N M1

TX Primary tumor cannot be assessed

T0 No evidence of primary tumor

T1 Tumor 2 cm, no extraparenchymal extension

T2 Tumor 2 cm, 4 cm, no extraparenchymal extension

T3 Tumor 4 cm or extraparenchymal extension (or both)

T4a Tumor invades skin, mandible, ear canal, facial nerve, or any of these structures

T4b Tumor invades skull base or pterygoid plates, or encases carotid artery

NX Regional lymph nodes cannot be assessed

N0 No cervical nodes metastasis

N1 Single ipsilateral lymph node 3 cm

N2a Single ipsilateral lymph node 3 cm and 6 cm

N2b Multiple ipsilateral lymph node metastases, each 6 cm

N2c Bilateral or contralateral lymph node metastases, each 6 cm

N3 Single or multiple lymph node metastases 6 cm

MX Distant metastases cannot be assessed

M0 No distant metastases

M1 Distant metastases present

Modified, with permission, from Greene FL, Page DL, Fleming ID et al (eds.):American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th ed. New York, Berlin, Heidelberg: Springer-Verlag, 2002.

Page 36: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Group 1: T1 and T2NO low-grade malignancy

Treatment is excision of the tumor with cuff of a normal tissue.

Facial nerve is preserved.

Regional lymph node evaluated at the time of surgery.

No post-op radio therapy unless the resection margin is not clear.

Page 37: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Group 2: T1 and T2NO high-grade malignancy

Treatment is total parotidectomy with excision of the first echolon node (digastric and submandibular nodes).

Facial nerve involvement:

a. patient with facial paralysis pre-operatively.

Resection of the facial nerve with primary grafting.

b. patient with normal facial function pre-op.

Resect the tumor of the facial and post-operative

wide field radiation.

Page 38: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Group 3: T3NO or any N+ high-grade or

recurrent cancer.

Treatment is total parotidectomy

Modified radical neck dissection

Post-operative wide field radiotherapy

Facial nerve as in group 2

Page 39: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Group 4: include all T4 tumor

Treatment is radical parotidectomy with modified radical neck dissection and resection of masseter muscle, part of the mandible or mastoid or ear canal as required.

Resection of the facial nerve with the tumor and primary grafting.

Followed by wide field post-operative radiotheray.

Page 40: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Points to remember in parotid surgery:

1. Pre-op evaluation: general condition of the patient, hemoglobin, LFT and U & E’s

2. Consenting patients for possible facial weakness.

3. Operating in bloodless field by:a. hypotensive techniqueb. elevation of the head of the bedc. delicate tissue handlingd. proper hemostasis

Page 41: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

4. Using facial nerve monitoring during operation and at the end of operation.

5. Exposure of the eye and the operative side of the face.

6. Modified blair incision.

7. Landmark for the facial nerve.

Page 42: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Indications of neck dissection1. Neck dissection is a recommended treatment of the

neck for the malignant salivary gland tumor, when?

2. If there is a clinically cervical adenopathies (15%).Parotid tumor bigger than 4cm, why?(the risk of occult metastasis over 20%).

3. High grade malignancy, why?(the risk of occult metastasis over 25%).

Page 43: Salivary Gland Neoplasm Dr. Saad Al-Muhayawi. M.D., FRCSC Associate Professor & Consultant ORL Head & Neck Surgery

Indications of post-operative radiotherapy

1. High-grade tumor

2. Gross or microscopic residual disease

3. Tumor involving or close to the facial nerve

4. Recurrent disease

5. Documented lymph node metastasis

6. Extraparotid extension

7. Deep lobe cancers

8. All T3 and T4 cancers